What can cause elevated Creatine Kinase (CK) levels, specifically CK Total of 152 U/L and CK Muscle Fraction (CK MF) of 9.9, in a psychiatric patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Elevated CK in Psychiatric Patients: Causes and Clinical Approach

Direct Answer

In a psychiatric patient with CK Total of 152 U/L and CK-MM of 9.9, the most likely causes are antipsychotic medication effects, recent physical activity or agitation, muscle trauma from restraints or falls, or underlying subclinical myopathy—with antipsychotic-induced CK elevation being particularly common in this population. 1

Understanding the CK Elevation

Context of These Values

  • CK Total of 152 U/L represents a mild elevation (typically 1-2 times the upper limit of normal, depending on laboratory reference ranges), which is commonly seen in psychiatric patients and does not indicate severe muscle damage 2, 1
  • The CK-MM fraction of 9.9 confirms skeletal muscle origin rather than cardiac involvement, as CK-MM is the predominant isoform in skeletal muscle 3, 4
  • This level of elevation does not suggest rhabdomyolysis or neuroleptic malignant syndrome, which typically show CK values of 500-3,000 IU/L or much higher 1

Primary Causes in Psychiatric Patients

1. Antipsychotic Medication Effects

  • Antipsychotic drugs can cause marked elevations in CK activity of the skeletal muscle (MM) form, with increases ranging from 1,206 to 177,363 IU/L in some cases, though most are asymptomatic 1
  • This occurs in approximately 10% of patients treated with antipsychotics including clozapine, olanzapine, risperidone, haloperidol, and loxapine 1
  • The onset can occur anywhere from 5 days to 2 years after initiating treatment, and elevations typically last 4-28 days (median 8 days) 1
  • Most patients with antipsychotic-induced CK elevation are asymptomatic, and the increases are often self-limiting even with continued treatment 1
  • The mechanism may involve increased cell membrane permeability in skeletal muscle, possibly related to serotonergic effects of these medications 1

2. Physical Activity and Agitation

  • Acute psychotic agitation and excessive physical activity commonly cause CK elevation in psychiatric patients 1
  • Strenuous or unaccustomed exercise, including eccentric muscle contractions, results in sarcomeric damage and increased serum CK that peaks at 24 hours and gradually returns to baseline with rest 2
  • In psychiatric settings, this includes struggling against restraints, pacing, or other repetitive movements during acute episodes 1

3. Muscle Trauma

  • Physical trauma from falls, restraints, or intramuscular injections can elevate CK levels 4
  • Skeletal muscle trauma can produce CK-MB elevation (up to 8.6% of trauma victims show CK-MB >5.0 EU/L) as part of increased total CK, even without cardiac injury 4
  • This is particularly relevant in psychiatric patients who may have falls or require physical intervention during acute episodes 1

4. Underlying Myopathy

  • Persistently increased CK levels may indicate early or subclinical muscle disease, which can be asymptomatic in pre-clinical stages 2
  • Approximately 9.9% of myasthenia gravis patients show CK elevation, and some have concomitant myositis or other neuromuscular diseases 5
  • Early myopathy may become manifest only after exercise or stress, making diagnosis challenging in resting patients 2

Essential Clinical Workup

Immediate Assessment

  • Obtain a detailed medication history, specifically documenting all antipsychotic medications, doses, duration of treatment, and any recent changes 1
  • Assess for muscle symptoms: Ask specifically about muscle soreness, tenderness, pain, weakness (particularly proximal muscles), or stiffness 3, 6
  • Evaluate recent physical activity: Document any recent agitation, restraint use, falls, intramuscular injections, or unusual physical exertion 2, 1
  • Screen for signs of neuroleptic malignant syndrome: Check for fever, rigidity, altered mental status, and autonomic instability—though CK of 152 U/L makes this unlikely 1

Laboratory Evaluation

  • Obtain cardiac troponin to exclude myocardial involvement, as biomarkers reflect myocardial damage regardless of mechanism 3
  • Check thyroid-stimulating hormone (TSH), as hypothyroidism predisposes to myopathy and can exacerbate muscle injury 3, 6, 7
  • Measure transaminases (AST, ALT) and LDH, which may be elevated reflecting enzymes released from muscle rather than liver injury 3
  • Consider vitamin D (25-OH) level, as deficiency is common (67.3% in one study) and may contribute to muscle symptoms 5
  • Evaluate for myositis-specific and myositis-associated antibodies (MSA/MAA) if clinical suspicion for inflammatory myopathy exists, though these are found in only 18.8% of patients with neuromuscular symptoms 5

Additional Testing When Indicated

  • Urinalysis for myoglobinuria to assess for rhabdomyolysis, though this is unlikely at CK 152 U/L 3, 1
  • Electromyography (EMG) and muscle MRI if weakness is present or underlying myopathy is suspected 3
  • Muscle biopsy should be reserved for cases where diagnosis remains uncertain after non-invasive testing 3

Management Approach

For Antipsychotic-Related Elevation

  • Continue current antipsychotic therapy if the patient is asymptomatic and CK is <10 times upper limit of normal, as these elevations are often self-limiting 6, 1
  • Monitor CK levels weekly if elevation persists or symptoms develop 3, 6
  • Consider dose reduction or switching to an alternative antipsychotic if CK continues to rise or symptoms emerge 6, 7
  • Do not routinely discontinue effective antipsychotic therapy for mild asymptomatic CK elevation, as this may destabilize psychiatric condition 1

For Exercise or Trauma-Related Elevation

  • Allow adequate rest and recovery time, as CK typically normalizes within 4-7 days after cessation of the inciting activity 2, 1
  • Repeat CK measurement after 1 week of rest to confirm downward trend 2
  • Implement fall prevention strategies and minimize use of physical restraints when possible 1

For Suspected Myopathy

  • Refer to neurology if CK remains persistently elevated after rest and medication adjustment, or if muscle weakness is present 3, 2
  • Counsel patients with suspected myopathy to continue physical activity at lower intensity to prevent muscle damage from high-intensity exercise while allowing adequate recovery 2
  • Consider that strength training may be safe even in patients with myopathy, though evidence for routine exercise prescription remains insufficient 2

Critical Pitfalls to Avoid

  • Do not assume all CK elevation in psychiatric patients represents neuroleptic malignant syndrome—mild elevations are common and usually benign 1
  • Do not overlook hypothyroidism as a contributing factor, as it significantly increases myopathy risk and is easily treatable 3, 6, 7
  • Do not dismiss normal or minimally elevated CK in symptomatic patients—some myopathies present with symptoms before significant CK elevation 6, 7
  • Do not routinely monitor CK in asymptomatic patients on antipsychotics, as this provides little clinical value and may lead to unnecessary medication changes 6, 1
  • Do not confuse CK-MB elevation from skeletal muscle trauma with myocardial injury—always correlate with troponin, ECG, and clinical context 4, 3
  • Do not immediately discontinue effective psychiatric medications for mild CK elevation without considering the risk-benefit ratio for the patient's mental health 1

References

Research

Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1996

Research

Creatine kinase monitoring in sport medicine.

British medical bulletin, 2007

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Mildly Elevated CK on Statin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Laboratory Evaluation for Body Aches in a Patient on Atorvastatin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.